FDA Approval for Provention Bio (PRVB).

Re-cork the Champagne! We were contemplating (dreaming) about an opening price over $12, and then a drift up towards $20, sometime during 2023. But no,...

Adding Ardelyx (ARDX) $1.57 to Watch List.

FDA Advisory Committee Says Go Forth Young Man! While we hadn't previously owned Ardelyx, nor are they a client - there are a number of...

Provention Biosciences (PRVB) Enters the Danger Zone.

Chart Looks Beautiful - But Nervous is why, we use soft and dry. LIVE QUOTE We'll be short and sweet. We make no prediction as for...

Revive Therapeutics (RVVTF) Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA

TORONTO, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company...

Revive (RVVTF) Hits a Snag?

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 First our summary."FDA provided communication that the amended protocol is still under...

Revive Therapeutics (RVVTF) Annual Shareholder Meeting.

ANNUAL SHAREHOLDER MEETING https://vimeo.com/752050831 CORPORATE PRESENTATION | AUGUST 2022 NEWS ARCHIVE

Adding Progressive Care (RXMD) $0.04 to Watch List.

Adding to Biotech Stock Review 2022 Watch List. Speculative, Yes. But Pay Down of $2 Million Toxic Note and Move into Remote Patient Monitoring Makes...

Provention Bio (PRVB) Announces $125 Million Term Loan Facility with Hercules Capital

Don't think we've ever seen anything like this before. Most investors who prefer to invest post FDA approval, invest post FDA approval. They got...
Dr John Fahy UCSF

Revive Therapeutics (RVVTF) Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company...

Revive Therapeutics (RVVTF) Enters the Danger Zone.

What Danger You Ask? Danger #1, the FDA doesn't like the data, and you own the stock. Danger #2, the FDA does like the data, and...

Latest article

Rick Rule Symposium – Conference Cheat Sheet

Natural Resource Investing Symposium - Presenter Guide We've attended hundreds and hundreds of Investment Conferences (Barclay, JP Morgan, LD Micro, Piper Sandler, Roth, VRIC) since...

GeoVax (GOVX) Surges 256%, With 207 Million Shares Trading!

What an Entertaining Week! ..and it's only Thursday. LIVE QUOTE (MAY 18TH) (MAY 21ST) So Where Does That Leave us Today? Yes, it was a pleasant surprise to see GeoVax...

Americore (AMCOF) Funding Launched. Looks Like Good Entry Point.

All Systems Go? A recently completed Magnetometer survey sends a strong signal to investors that the company is advancing its project in a disciplined, data-driven...